Background Data are scarce on immunogenicity of COVID-19 vaccines in patients with
autoimmune diseases, who are often treated with immunosuppressive drugs. We aimed to …

Background Disease-specific studies have reported impaired humoral responses after
SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders treated with …

Background Concerns have been raised regarding the risks of SARS-CoV-2 breakthrough
infections in vaccinated patients with immune-mediated inflammatory diseases treated with …

Background: Patients affected by different types of autoimmune diseases, including common
conditions such as multiple sclerosis (MS) and rheumatoid arthritis (RA), are often treated …

Background Studies have suggested incremental short-term adverse events (AE) after
repeated vaccination. In this report, we assessed occurrence and risk factors for short-term AEs …

Objectives To evaluate whether a third vaccination shows an added effect on severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) T-cell responses in patients with multiple …

Objectives To compare the cumulative incidence and disease severity of reported SARS-CoV-2
omicron breakthrough infections between patients with immune-mediated inflammatory …

Background Research on the disease severity of COVID-19 in patients with rheumatic
immune-mediated inflammatory diseases (IMIDs) has been inconclusive, and long-term …

Since the emergence of the omicron (B. 1.1. 529) variant of SARS-CoV-2, the burden of
COVID-19 disease on health care has decreased, with rates of hospitalisation due to COVID-19 …

Background It is unclear which patients with multiple sclerosis (MS) are most susceptible for
omicron breakthrough infections. Methods We assessed omicron breakthrough infections in …